Insights into pemigatinib and the recent FDA approval of this agent

Insights into pemigatinib and the recent FDA approval of this agent

FDA Approved Pemigatinib new drug for cholangiocarcinoma, $18, 448 For 14 Days, But I'm 2 Die 2Подробнее

FDA Approved Pemigatinib new drug for cholangiocarcinoma, $18, 448 For 14 Days, But I'm 2 Die 2

The impact of the FDA approval of pemigatinibПодробнее

The impact of the FDA approval of pemigatinib

Just the Facts: Orthocell achieves FDA study milestone for Remplir™ nerve repair productПодробнее

Just the Facts: Orthocell achieves FDA study milestone for Remplir™ nerve repair product

Drug, Diagnostic and Device Development: From Scientific Findings to FDA ApprovalПодробнее

Drug, Diagnostic and Device Development: From Scientific Findings to FDA Approval

AC21 - Ghassan Abou-Alfa: FGFRПодробнее

AC21 - Ghassan Abou-Alfa: FGFR

The recent FDA approval of teclistamab for R/R multiple myelomaПодробнее

The recent FDA approval of teclistamab for R/R multiple myeloma

WEBINAR: The Aduhelm FDA Approval: Fresh Insights and OpportunitiesПодробнее

WEBINAR: The Aduhelm FDA Approval: Fresh Insights and Opportunities

FDA approval of pemigatinib for R/R myeloid/lymphoid neoplasms: a major advance in the fieldПодробнее

FDA approval of pemigatinib for R/R myeloid/lymphoid neoplasms: a major advance in the field

The promise of pemigatinib for patients with FGFR1-rearranged MLNПодробнее

The promise of pemigatinib for patients with FGFR1-rearranged MLN

FIGHT-202: pemigatinib in CCAПодробнее

FIGHT-202: pemigatinib in CCA

FDA approval of lotilaner - XdemvyПодробнее

FDA approval of lotilaner - Xdemvy

An insight into clinical risk factors for progression in MPNsПодробнее

An insight into clinical risk factors for progression in MPNs

An insight into the management of cytopenias in MFПодробнее

An insight into the management of cytopenias in MF

FDA ApprovalПодробнее

FDA Approval

The pharmacokinetics of pirtobrutinibПодробнее

The pharmacokinetics of pirtobrutinib

FGFR2 Inhibitors in Advanced CholangiocarcinomaПодробнее

FGFR2 Inhibitors in Advanced Cholangiocarcinoma

How can we deal with the explosion of new treatments? - FDAПодробнее

How can we deal with the explosion of new treatments? - FDA

Exciting updates in MF: novel targets and agentsПодробнее

Exciting updates in MF: novel targets and agents